Legend Biotech's CARVYKTI® proves significant overall survival improvement in second line multiple myeloma patients.
Legend Biotech's CARVYKTI® is the first cell therapy proven to significantly improve overall survival in multiple myeloma patients, starting from the second line of treatment. This breakthrough offers a new option compared to standard therapies, marking a significant advancement in the management of this cancer.
September 27, 2024
5 Articles